The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
The collaboration will center on expanding access to Eastman’s Esmeri technology
Subscribe To Our Newsletter & Stay Updated